7,8,4′-Trihydroxyisoflavone attenuates DNCB-induced atopic dermatitis-like symptoms in NC/Nga mice

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Kim, Heejung ^a   Kim, Jong Rhan ^a,b   Kang, Heerim ^a   Choi, Jinhwan ^a   Yang, Hee ^a   Lee, Pomjoo ^b   Kim, Jiyoung ^c,d   Lee, Ki Won ^a,b,c,d  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

7,8,4' TRIHYDROXYISOFLAVONE; ANTIPRURITIC AGENT; GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; TACROLIMUS; UNCLASSIFIED DRUG; 1 CHLORO 2,4 DINITROBENZENE; 7,8,4'-TRIHYDROXYISOFLAVONE; ANTIINFLAMMATORY AGENT; CYTOKINE; ISOFLAVONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOPIC DERMATITIS; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EOSINOPHIL; FEMALE; HISTOPATHOLOGY; IMMUNOGLOBULIN BLOOD LEVEL; MAST CELL; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; SKIN WATER LOSS; ANIMAL; BLOOD; CHEMICALLY INDUCED; DERMATITIS, ATOPIC; DRUG EFFECTS; IMMUNOLOGY; PATHOLOGY; SKIN;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; DERMATITIS, ATOPIC; DINITROCHLOROBENZENE; FEMALE; IMMUNOGLOBULIN E; ISOFLAVONES; MICE; SKIN;

EID: 84929511426     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104938     Document Type: Article

References (46)

1. Leung DY (1997) Atopic dermatitis: immunobiology and treatment with immune modulators. Clin Exp Immunol 107 Suppl 1: 25-30.
2. Bieber T (2008) Atopic dermatitis. N Engl J Med 358: 1483-1494.
3. Marsella R, Olivry T, Carlotti DN, International Task Force on Canine Atopic D (2011) Current evidence of skin barrier dysfunction in human and canine atopic dermatitis. Vet Dermatol 22: 239-248.
4. Leung DY, Bieber T (2003) Atopic dermatitis. Lancet 361: 151-160. (Pubitemid 36092023)
5. Soter NA (1989) Morphology of atopic eczema. Allergy 44 Suppl 9: 16-19.
6. Leung DY, Soter NA (2001) Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 44: S1-S12. (Pubitemid 32047908)
7. Sandoval-Lopez G, Teran LM (2001) TARC: novel mediator of allergic inflammation. Clin Exp Allergy 31: 1809-1812. (Pubitemid 34014725)
8. Vestergaard C, Yoneyama H, Murai M, Nakamura K, Tamaki K, et al. (1999) Overproduction of Th2-specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. J Clin Invest 104: 1097-1105. (Pubitemid 29536320)
9. Spergel JM, Mizoguchi E, Oettgen H, Bhan AK, Geha RS (1999) Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis. J Clin Invest 103: 1103-1111. (Pubitemid 29207243)
10. Chen L, Martinez O, Overbergh L, Mathieu C, Prabhakar BS, et al. (2004) Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model. Clin Exp Immunol 138: 375-387. (Pubitemid 39573615)
11. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA (2004) New insights into atopic dermatitis. J Clin Invest 113: 651-657. (Pubitemid 38544154)
12. Blume-Peytavi U, Wahn U (2011) Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate. J Eur Acad Dermatol Venereol 25: 508-515.
13. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ (2006) Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 54: 1-15; quiz 16-18.
14. Jin H, He R, Oyoshi M, Geha RS (2009) Animal models of atopic dermatitis. J Invest Dermatol 129: 31-40.
15. Takeda K, Gelfand EW (2009) Mouse models of allergic diseases. Curr Opin Immunol 21: 660-665.
16. Jung BG, Cho SJ, Koh HB, Han DU, Lee BJ (2010) Fermented Maesil (Prunus mume) with probiotics inhibits development of atopic dermatitis-like skin lesions in NC/Nga mice. Vet Dermatol 21: 184-191.
17. Pokharel YR, Lim SC, Kim SC, Heo TH, Choi HK, et al. (2008) Sopungyangjae-tang inhibits development of dermatitis in nc/nga mice. Evid Based Complement Alternat Med 5: 173-180. (Pubitemid 351786663)
18. Fujii Y, Takeuchi H, Sakuma S, Sengoku T, Takakura S (2009) Characterization of a 2,4-dinitrochlorobenzene-induced chronic dermatitis model in rats. Skin Pharmacol Physiol 22: 240-247.
19. Ikoma A (2009) Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: mechanisms and management of itch in atopic dermatitis. J Pharmacol Sci 110: 265-269.
20. Hattori K, Nishikawa M, Watcharanurak K, Ikoma A, Kabashima K, et al. (2010) Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization. J Immunol 184: 2729-2735.
21. Zhang EY, Chen AY, Zhu BT (2009) Mechanism of dinitrochlorobenzene- induced dermatitis in mice: role of specific antibodies in pathogenesis. PLoS One 4: e7703.
22. Eldridge AC, Kwolek WF (1983) Soybean isoflavones: effect of environment and variety on composition. J Agric Food Chem 31: 394-396.
23. Duan W, Kuo IC, Selvarajan S, Chua KY, Bay BH, et al. (2003) Antiinflammatory effects of genistein, a tyrosine kinase inhibitor, on a guinea pig model of asthma. Am J Respir Crit Care Med 167: 185-192. (Pubitemid 36076078)
24. Sakai T, Kogiso M, Mitsuya K, Komatsu T, Yamamoto S (2006) Genistein suppresses development of spontaneous atopic-like dermatitis in NC/Nga mice. J Nutr Sci Vitaminol (Tokyo) 52: 293-296. (Pubitemid 44520059)
25. Verdrengh M, Jonsson IM, Holmdahl R, Tarkowski A (2003) Genistein as an anti-inflammatory agent. Inflamm Res 52: 341-346. (Pubitemid 36995159)
26. Seo MH, Kim BN, Kim KR, Lee KW, Lee CH, et al. (2013) Production of 8-hydroxydaidzein from soybean extract by Aspergillus oryzae KACC 40247. Biosci Biotechnol Biochem 77: 1245-1250.
27. Leung DY, Hirsch RL, Schneider L, Moody C, Takaoka R, et al. (1990) Thymopentin therapy reduces the clinical severity of atopic dermatitis. J Allergy Clin Immunol 85: 927-933. (Pubitemid 20173131)
28. Takano N, Arai I, Kurachi M (2003) Analysis of the spontaneous scratching behavior by NC/Nga mice: a possible approach to evaluate antipruritics for subjects with atopic dermatitis. Eur J Pharmacol 471: 223-228. (Pubitemid 36776418)
29. Kotani M, Matsumoto M, Fujita A, Higa S, Wang W, et al. (2000) Persimmon leaf extract and astragalin inhibit development of dermatitis and IgE elevation in NC/Nga mice. J Allergy Clin Immunol 106: 159-166. (Pubitemid 30482866)
30. Oku H, Ishiguro K (2001) Antipruritic and antidermatitic effect of extract and compounds of Impatiens balsamina L. in atopic dermatitis model NC mice. Phytother Res 15: 506-510. (Pubitemid 32906435)
31. Ziment I, Tashkin DP (2000) Alternative medicine for allergy and asthma. J Allergy Clin Immunol 106: 603-614.
32. Mahn K, Borras C, Knock GA, Taylor P, Khan IY, et al. (2005) Dietary soy isoflavone induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo. FASEB J 19: 1755-1757. (Pubitemid 41429553)
33. Sakai T, Kogiso M (2008) Soy isoflavones and immunity. J Med Invest 55: 167-173.
34. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S, et al. (2003) Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst 95: 906-913. (Pubitemid 36833882)
35. Chun J, Kim GM, Lee KW, Choi ID, Kwon GH, et al. (2007) Conversion of isoflavone glucosides to aglycones in soymilk by fermentation with lactic acid bacteria. J Food Sci 72: M39-44. (Pubitemid 46392388)
36. Lee DE, Lee KW, Byun S, Jung SK, Song N, et al. (2011) 7,3′,4′-Trihydroxyisoflavone, a metabolite of the soy isoflavone daidzein, suppresses ultraviolet B-induced skin cancer by targeting Cot and MKK4. J Biol Chem 286: 14246-14256.
37. Lo YL, Wang W, Ho CT (2012) 7,3′,4′-Trihydroxyisoflavone modulates multidrug resistance transporters and induces apoptosis via production of reactive oxygen species. Toxicology 302: 221-232.
38. Williams CM, Galli SJ (2000) Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J Exp Med 192: 455-462. (Pubitemid 30629171)
39. Grewe M, Bruijnzeel-Koomen CA, Schopf E, Thepen T, Langeveld-Wildschut AG, et al. (1998) A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 19: 359-361. (Pubitemid 28392277)
40. Ong PY, Leung DY (2006) Immune dysregulation in atopic dermatitis. Curr Allergy Asthma Rep 6: 384-389. (Pubitemid 44340170)
41. Trautmann A, Akdis M, Kleemann D, Altznauer F, Simon HU, et al. (2000) T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest 106: 25-35. (Pubitemid 30437237)
42. Boguniewicz M, Leung DY (2011) Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 242: 233-246.
43. Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, et al. (2009) Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 129: 1892-1908.
44. Elias PM, Hatano Y, Williams ML (2008) Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 121: 1337-1343.
45. Lee CH, Yu HS (2011) Biomarkers for itch and disease severity in atopic dermatitis. Curr Probl Dermatol 41: 136-148.
46. Angelova-Fischer I, Bauer A, Hipler UC, Petrov I, Kazandjieva J, et al. (2005) The objective severity assessment of atopic dermatitis (OSAAD) score: validity, reliability and sensitivity in adult patients with atopic dermatitis. Br J Dermatol 153: 767-773. (Pubitemid 41415903)